ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report released on Thursday morning,Benzinga reports. The firm currently has a $30.00 target price on the stock.

Other equities analysts also recently issued research reports about the stock. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd. Piper Sandler cut their price target on shares of ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a report on Monday, August 19th.

ImmunityBio Stock Up 2.2 %

IBRX opened at $5.21 on Thursday. ImmunityBio has a 52-week low of $3.10 and a 52-week high of $10.53. The company has a market cap of $3.63 billion, a P/E ratio of -5.54 and a beta of 0.99. The firm’s 50-day moving average price is $4.27 and its 200-day moving average price is $5.15.

Hedge Funds Weigh In On ImmunityBio

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in ImmunityBio by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 13,539,590 shares of the company’s stock worth $72,708,000 after buying an additional 211,065 shares during the period. State Street Corp grew its stake in shares of ImmunityBio by 10.1% during the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after purchasing an additional 790,408 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of ImmunityBio by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,265,981 shares of the company’s stock worth $4,709,000 after purchasing an additional 29,665 shares during the period. Bank of New York Mellon Corp grew its stake in shares of ImmunityBio by 37.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company’s stock worth $3,928,000 after purchasing an additional 170,742 shares during the period. Finally, Clearwater Capital Advisors LLC grew its stake in shares of ImmunityBio by 8.9% during the 2nd quarter. Clearwater Capital Advisors LLC now owns 482,549 shares of the company’s stock worth $3,050,000 after purchasing an additional 39,250 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.